Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2026
Novartis recalls Diovan valsartan batch over dissolution specification failure
Recall announced
Novartis recalled a specific batch of its Diovan (valsartan) blood pressure drug after it failed to meet dissolution specifications, potentially reducing effectiveness. The FDA classified the notice as a Class II recall, warning of possible temporary or medically reversible adverse health consequences. The affected batch, marked AV5913C, consists of 90-count 160-mg tablets expiring June 2027, manufactured by Pantheon Manufacturing Services in Greenville, North Carolina and distributed nationwide in the US.
Company response
Recall — Novartis
Novartis made the recall on August 4.
Source excerpt
The batch that is being recalled has AV5913C on the packaging and include packages of 90 160-mg tablets with an expiration date of June 2027.
The valsartan drug was made by Novartis under the brand name Diovan and has been recalled as it does not meet dissolution specifications.
The US Food and Drug Administration has determined the notice as a Class II recall, which means exposure to the drug may lead to “temporary or medically reversible adverse health consequences.”